Apollomics Inc. (APLM) stock
Close on Nov 11, 2026Market cap $40.85MP/E –Yield –
Apollomics Inc. reported revenue of $8.50M for fiscal 2025. At the latest close the market valued the company at $40.85M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $40.85M
- P/E ratio
- –
- Price to sales
- 4.81
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $8.50M
- EPS, diluted
- -$7.57
Trading
- Previous close
- $18.60
- Open
- $18.60
- Day's range
- $18.60 – $18.60
- Average volume (20 days)
- 21,717
- Beta (5 years)
- 0.69
- 52-week range
- $12.58 – $28.29
- RSI (14 days)
- 39.5
- Volatility (1 year)
- 110.6%
- WACC
- 8.3%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | APLM | S&P 500 | Difference | APLM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.5% | -2.4% | −11.1 pts | ||
| 3 months | +2.4% | -1.2% | +3.6 pts | ||
| Year to date | -0.5% | +12.3% | −12.8 pts | ||
| 1 year | +21.5% | +12.4% | +9.0 pts | ||
| 3 years | -77.3% | +78.8% | −156.1 pts | -39.0% | +21.4% |
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Apollomics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Apollomics
Pharmaceutical Preparations
Apollomics Inc. is a clinical-stage biopharmaceutics enterprise focused on the discovery and clinical advancement of oncology therapies. The organization concentrates on advancing drug candidates designed to address challenging and resistant cancers by leveraging pipeline developments, research licensing agreements, and drug supply collaborations. Its clinical and research programs aim to meet patient needs across global oncology markets, engaging with international healthcare institutions and pharmaceutical research partners.
Company profile, executives and historyApollomics stock: common questions
What is Apollomics's stock price?
APLM closed at $18.60 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $12.58 and $28.29.
What is Apollomics's market cap?
Apollomics was worth $40.85M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is APLM's P/E ratio?
Apollomics lost money over fiscal 2025 (diluted EPS -$7.57), so it has no meaningful P/E ratio.
How much revenue does Apollomics make?
Apollomics reported revenue of $8.50M for fiscal 2025.
Does Apollomics pay a dividend?
No. Apollomics has not paid a cash dividend over the last twelve months.
How has APLM stock performed over the past year?
Including dividends, APLM returned +21.5% over the past year, against +12.4% for the S&P 500.
Who are Apollomics's competitors?
Companies most similar to Apollomics by business, industry and size include CBIO, ADAG, ANL, KYNB, IMNM.
See a number that looks wrong?